THE COMBATING ANTIBIOTIC RESISTANT BACTERIA BIOPHARMACEUTICAL ACCELERATOR ‘CARB-X' (360G-Wellcome-208608_Z_17_Z)

£124,959,820

The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) brings together leaders from industry, philanthropy, government and academia. It is a collaboration between the Biomedical Advanced Research and Development Authority (“BARDA”), the National Institute of Allergy and Infectious Diseases (“NIAID”), both within the US Department of Health and Human Services, and the Trustees of Boston University (“BU”). The international partnership will support a suite of products through early preclinical development. CARB-X aims to get products to a stage where private or public investors can then take them forward.

Where is this data from?

This data was originally published by The Wellcome Trust. If you need to report a problem in the data please contact The Wellcome Trust directly, see their GrantNav publisher page for more information.

Grant Details

Amount Awarded 124959820
Applicant Surname Outterson
Approval Committee Internal Decision Panel
Award Date 2017-05-15T00:00:00+00:00
Financial Year 2016/17
Grant Programme: Title Discretionary award – DRI
Internal ID 208608/Z/17/Z
Lead Applicant Prof Kevin Outterson
Planned Dates: End Date 2021-07-31T00:00:00+00:00
Planned Dates: Start Date 2017-04-01T00:00:00+00:00
Recipient Org: Country United States
Region International